Evidence map›Paper›PMID 35343796›Full record

Trial reportmSystems2022

Bifidobacterium lactis Probio-M8 Adjuvant Treatment Confers Added Benefits to Patients with Coronary Artery Disease via Target Modulation of the Gut-Heart/-Brain Axes.

Baoqing Sun, Teng Ma, Yalin Li, Ni Yang, Bohai Li, Xinfu Zhou, Shuai Guo, Shukun Zhang, Lai-Yu Kwok, Zhihong Sun and 1 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in mSystems, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. mSystems · 2025
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Metabolic syndrome and a broken heart: trust your gut or risk your heart.American journal of physiology. Heart and circulatory physiology · 2026
    Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Baoqing Sun *Department of Cardiology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, Shandong, China.
Teng Ma *Inner Mongolia Key Laboratory of Dairy Biotechnology and Engineering, Inner Mongolia Agricultural Universitygrid.411638.9, Hohhot, Inner Mongolia, China.
Yalin Li *Inner Mongolia Key Laboratory of Dairy Biotechnology and Engineering, Inner Mongolia Agricultural Universitygrid.411638.9, Hohhot, Inner Mongolia, China.
Ni YangInner Mongolia Key Laboratory of Dairy Biotechnology and Engineering, Inner Mongolia Agricultural Universitygrid.411638.9, Hohhot, Inner Mongolia, China.
Bohai LiInner Mongolia Key Laboratory of Dairy Biotechnology and Engineering, Inner Mongolia Agricultural Universitygrid.411638.9, Hohhot, Inner Mongolia, China.
Xinfu ZhouDepartment of Cardiology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, Shandong, China.
Shuai GuoInner Mongolia Key Laboratory of Dairy Biotechnology and Engineering, Inner Mongolia Agricultural Universitygrid.411638.9, Hohhot, Inner Mongolia, China.
Shukun ZhangDepartment of Pathology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, Shandong, China.
Lai-Yu KwokInner Mongolia Key Laboratory of Dairy Biotechnology and Engineering, Inner Mongolia Agricultural Universitygrid.411638.9, Hohhot, Inner Mongolia, China.
Zhihong SunInner Mongolia Key Laboratory of Dairy Biotechnology and Engineering, Inner Mongolia Agricultural Universitygrid.411638.9, Hohhot, Inner Mongolia, China.ORCID 0000-0002-7605-2048
Heping ZhangInner Mongolia Key Laboratory of Dairy Biotechnology and Engineering, Inner Mongolia Agricultural Universitygrid.411638.9, Hohhot, Inner Mongolia, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accumulating evidence suggests that gut dysbiosis may play a role in cardiovascular problems like coronary artery disease (CAD). Thus, target steering the gut microbiota/metabolome via probiotic administration could be a promising way to protect against CAD. A 6-month randomized, double-blind, placebo-controlled clinical trial was conducted to investigate the added benefits and mechanism of the probiotic strain, Bifidobacterium lactis Probio-M8, in alleviating CAD when given together with a conventional regimen. Sixty patients with CAD were randomly divided into a probiotic group (

Indexed as

Adjuvants, ImmunologicBifidobacterium animalisCoronary Artery DiseaseAdjuvants, PharmaceuticAtorvastatinBrainHumansMetoprololAdjuvants, ImmunologicAdjuvants, PharmaceuticAtorvastatinMetoprololBifidobacterium lactis Probio-M8Coronary artery diseasegut-brain axisgut-heart axisgut-heart/brain axesmetabolomicsspecies-level genome bins (SGBs)

Identifiers

PMID35343796
PMCPMC9040731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.